Shay Capital’s Tango Therapeutics TNGX Stock Holding History

Shay Capital’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-17,500	Closed	-$133K	–	606
2022 Q1	$133K	Buy	+17,500	New	+$152K	0.02%	403

Other funds holding TNGX

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Shay Capital's TNGX Position: Q2 2022 in Review

Shay Capital sold out of Tango Therapeutics (TNGX) in Q2 2022, closing a stake of 17,500 shares — an estimated $133K sold.

Shay Capital first reported a position in TNGX in Q1 2022 and held it in 1 quarter. The position peaked at $133K in Q1 2022. 77 funds tracked by Wall St. Rank hold TNGX as of Q2 2022.

Shay Capital reported no remaining Tango Therapeutics position as of Q2 2022 after selling out during the quarter.
Shay Capital sold 17,500 Tango Therapeutics shares in Q2 2022, an estimated $133K.
Shay Capital first reported a position in Tango Therapeutics in Q1 2022 and held it in 1 quarter.
Shay Capital's Tango Therapeutics position peaked at $133K in Q1 2022.
77 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2022.

Based on Shay Capital's 13F filing for Q2 2022, filed 15 Aug 2022.